Eloxx Pharmaceuticals (NASDAQ: ELOX) shares spiked higher after the company presented data for its lead investigational drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference.
ELX-02 is focused on the development for cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.
Cystic fibrosis is caused by the absence or dysfunction of a protein called CFTR that controls the movement of salt and water in an out of cells. ELX-02 has shown increased CFTR function in organoids bearing nonsense alleles representing more than 75 percent of the cystic fibrosis nonsense genotype population.
Eloxx will report top-line data from Phase 2 clinical trial in cystic fibrosis later this year. For now, the Phase 2 protocol has been reviewed and approved by the European Cystic Fibrosis Society-Clinical Trial Network and given a score of “high priority.”
On Thursday afternoon, Eloxx Pharmaceuticals shares traded up 25.7 percent to $11.20.
Insys Therapeutics Board Members Resign After 5M DOJ Settlement
ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study
See more from Benzinga
- Google's Stadia Video Game Platform Announces Pricing, Games Structure
- Citron Research Targets Fleetcor Technologies, Calls For CEO's Resignation
- Insys Therapeutics Board Members Resign After 5M DOJ Settlement
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.